Skip to main content
Premium Trial:

Request an Annual Quote

Third Wave's HPV Tests To Use Agencourt Bioscience's Sample-Prep System

NEW YORK (GenomeWeb News) - Beckman Coulter subsidiary Agencourt Bioscience said today that Third Wave Technologies will use its Genfind DNA-isolation system for two human papillomavirus tests that it expects to market in 2009.
 
Third Wave, now a wholly owned subsidiary of Hologic, submitted its Cervista HPV HR and Cervista HPV 16/18 tests to the US Food and Drug Administration for pre-market approval in April.
 
The companies said that they are also collaborating on the development of “future applications” for Agencourt’s nucleic acid preparation technology, but did not provide further details of their plans.
 
Genfind is based on Agencourt’s Solid Phase Reversible Immobilization paramagnetic bead-based nucleic acid purification technology, which eliminates the need for solvents, vacuum filtration, or centrifugation steps, the company said.
 
Kevin Conroy, president and CEO of Third Wave, said in a statement that Agencourt’s Genfind technology delivers “reliable high recovery of purified DNA” and is easily automated.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.